尤物视频污,99热99热99超碰,精品久久久久女少妇,少妇精品无码,日B视屏久久香色,亚洲美女午夜福利av,国产美女被操,国产九九精品,国产久久色情

Wuhan Fuxing Biological Pharmaceutical Co., Ltd. is a holding subsidiary of Fuxing Group, one of China's top 500 private enterprises. Established in July 2001 through the acquisition of the former "Hanchuan Pharmaceutical Factory," it is a modern high-tech enterprise integrating drug research and development, production, and sales. Over the years, the company has adhered to the philosophy of "dedicating to public health and longevity, improving the quality of human life," and strictly implemented the quality policy of "controlling product quality from prevention, ensuring safety and effectiveness through standardized details; guaranteeing leading quality through continuous improvement, and serving public health with high-quality medicines" to ensure the safety and efficacy of medicines for the public. It has been recognized as a "Double Excellence" enterprise in Chinese pharmaceutical quality and integrity, one of "China's Top 50 Growing Pharmaceutical Enterprises," a "Specialized, Refined, Unique, and New" Little Giant Enterprise in Hubei Province, and an enterprise under the "Cultivation of Hidden Champions in Key Segments of Hubei's Pillar Industries."

The company covers an area of 160,000 square meters and currently employs 275 people, including 29 with bachelor's degrees or higher and 71 technical professionals in pharmaceutical-related fields. It holds 116 approvals for traditional Chinese and Western medicine formulations, with 54 varieties included in the National Essential Medicines List. It is equipped with over 130 sets of advanced testing instruments and production equipment.

Production scope: Modern high-speed production lines for large-volume injections (plastic bottles, glass bottles, upright polypropylene infusion bags, multi-layer co-extruded infusion soft bags), small-volume injections, hard capsules, granules, tablets, and more.

Business scope: Licensed projects: Drug production, drug contract manufacturing, drug import and export (projects subject to approval by law may only be carried out after approval by relevant departments). Specific business projects are subject to approval documents or permits from relevant departments. General projects: Production of traditional Chinese medicine extracts, manufacturing of medical packaging materials, technical services, technical development, technical consulting, technical exchanges, technology transfer, and technology promotion (except for licensed businesses, the company may independently operate projects not prohibited or restricted by laws and regulations).

New product development partners: Since its establishment, the company has consistently adhered to the strategy of "increasing efficiency through innovation, seeking development through enhancement," and has established long-term research collaborations with multiple scientific research institutions such as Hubei Pharmaceutical Industry Research Institute, Frontage Laboratories, Beijing Xinkaiyuan, and Qingdao Aoruisen, laying a solid foundation for the company's development.

Ambitious technical team: The company holds three invention patents, including "A Novel Preparation Method for Banxia Hewei Traditional Chinese Medicine," and eight utility model patents, such as "Air Valve System for Purification Air Conditioning Units." The technical team has been recognized as a "Key Industrial Technology Innovation Team in Hubei Province" and a "Key Industrial Technology Innovation Team in Xiaogan City." The company's self-developed "Banxia Hewei Granules" was awarded "National Key New Product" by four ministries including the Ministry of Science and Technology and the Ministry of Commerce, included in the National Medical Insurance Directory in 2019, and is produced exclusively by the company nationwide.